Literature DB >> 33002503

Approach to Eosinophilia Presenting With Pulmonary Symptoms.

Chen E Rosenberg1, Paneez Khoury2.   

Abstract

Eosinophilia with pulmonary involvement is characterized by the presence of peripheral blood eosinophilia, typically ≥500 cells/mm3, by pulmonary symptoms and physical examination findings that are nonspecific, and by radiographic evidence of pulmonary disease and is further supported by histopathologic evidence of tissue eosinophilia in a lung or pleura biopsy specimen and/or increased eosinophils in BAL fluid, usually >10%. Considering that there are a variety of underlying causes of eosinophilia with pulmonary manifestations and overlapping clinical, laboratory, and radiologic features, it is essential to approach the evaluation of eosinophilia with pulmonary findings systematically. In this review, we will describe a case presentation and discuss the differential diagnosis, a directed approach to the diagnostic evaluation and supporting literature, the current treatment strategies for pulmonary eosinophilia syndromes, and the levels of evidence underlying the recommendations, where available. Overall, optimal management of eosinophilic lung disease presentations are directed at the underlying cause when identifiable, and the urgency of treatment may be guided by the presence of severe end-organ involvement or life-threatening complications. When an underlying cause is not easily attributable, management of eosinophilia with pulmonary involvement largely relies on eosinophil-directed interventions, for which biologic therapies are increasingly being used. Published by Elsevier Inc.

Entities:  

Keywords:  asthma; eosinophilia; eosinophilic granulomatosis with polyangiitis hypereosinophilic; syndrome

Mesh:

Substances:

Year:  2020        PMID: 33002503      PMCID: PMC8039005          DOI: 10.1016/j.chest.2020.09.247

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  56 in total

1.  A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma.

Authors:  Ritesh Agarwal; Ashutosh N Aggarwal; Sahajal Dhooria; Inderpaul Singh Sehgal; Mandeep Garg; Biman Saikia; Digambar Behera; Arunaloke Chakrabarti
Journal:  Eur Respir J       Date:  2015-11-19       Impact factor: 16.671

2.  Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.

Authors:  Matthieu Groh; Christian Pagnoux; Chiara Baldini; Elisabeth Bel; Paolo Bottero; Vincent Cottin; Klaus Dalhoff; Bertrand Dunogué; Wolfgang Gross; Julia Holle; Marc Humbert; David Jayne; J Charles Jennette; Romain Lazor; Alfred Mahr; Peter A Merkel; Luc Mouthon; Renato Alberto Sinico; Ulrich Specks; Augusto Vaglio; Michael E Wechsler; Jean-François Cordier; Loïc Guillevin
Journal:  Eur J Intern Med       Date:  2015-05-09       Impact factor: 4.487

3.  Pediatric Hypereosinophilia: Characteristics, Clinical Manifestations, and Diagnoses.

Authors:  Dara Burris; Chen E Rosenberg; Justin T Schwartz; Yin Zhang; Michael D Eby; J Pablo Abonia; Patricia C Fulkerson
Journal:  J Allergy Clin Immunol Pract       Date:  2019-05-22

4.  Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia.

Authors:  Hatice Kaya; Seyfettin Gümüş; Ergun Uçar; Mehmet Aydoğan; Uğur Muşabak; Ergun Tozkoparan; Hayati Bilgiç
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

Review 5.  A Review of Clinical and Imaging Findings in Eosinophilic Lung Diseases.

Authors:  Adam Bernheim; Theresa McLoud
Journal:  AJR Am J Roentgenol       Date:  2017-02-22       Impact factor: 3.959

Review 6.  Non-asthmatic eosinophilic bronchitis and its relationship with asthma.

Authors:  Kefang Lai; Ruchong Chen; Wen Peng; Wenzhi Zhan
Journal:  Pulm Pharmacol Ther       Date:  2017-07-05       Impact factor: 3.410

7.  Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial.

Authors:  Xavier Puéchal; Christian Pagnoux; Gabriel Baron; François Lifermann; Loïk Geffray; Thomas Quémeneur; Jean-Luc Saraux; Marie Wislez; Vincent Cottin; Marc Ruivard; Nicolas Limal; Achille Aouba; Bernard Bonnotte; Antoine Néel; Christian Agard; Pascal Cohen; Benjamin Terrier; Claire Le Jeunne; Luc Mouthon; Philippe Ravaud; Loïc Guillevin
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

8.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Authors:  Marc E Rothenberg; Amy D Klion; Florence E Roufosse; Jean Emmanuel Kahn; Peter F Weller; Hans-Uwe Simon; Lawrence B Schwartz; Lanny J Rosenwasser; Johannes Ring; Elaine F Griffin; Ann E Haig; Paul I H Frewer; Jacqueline M Parkin; Gerald J Gleich
Journal:  N Engl J Med       Date:  2008-03-16       Impact factor: 91.245

9.  Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

Authors:  Vincent Cottin; Elisabeth Bel; Paolo Bottero; Klaus Dalhoff; Marc Humbert; Romain Lazor; Renato A Sinico; Pasupathy Sivasothy; Michael E Wechsler; Matthieu Groh; Sylvain Marchand-Adam; Chahéra Khouatra; Benoit Wallaert; Camille Taillé; Philippe Delaval; Jacques Cadranel; Philippe Bonniaud; Grégoire Prévot; Sandrine Hirschi; Anne Gondouin; Bertrand Dunogué; Gérard Chatté; Christophe Briault; Christian Pagnoux; David Jayne; Loïc Guillevin; Jean-François Cordier
Journal:  Autoimmun Rev       Date:  2016-09-23       Impact factor: 9.754

10.  Aspirin desensitization therapy in aspirin-exacerbated respiratory disease: a systematic review.

Authors:  Natasha Larivée; Christopher J Chin
Journal:  Int Forum Allergy Rhinol       Date:  2020-01-16       Impact factor: 3.858

View more
  2 in total

1.  Response.

Authors:  Chen E Rosenberg; Paneez Khoury
Journal:  Chest       Date:  2021-04-06       Impact factor: 9.410

2.  Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series.

Authors:  Hiroki Tashiro; Koichiro Takahashi; Yuki Kurihara; Hironori Sadamatsu; Yuki Kuwahara; Shinya Kimura; Naoko Sueoka-Aragane
Journal:  J Asthma Allergy       Date:  2022-02-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.